| Product Name |
Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Variant, South African Variant |
| Catalog Number |
EG-342 |
| Description |
Lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1, GenBank: QHD43416.1, South African variant, B.1.351), stabilized as a trimer (HexaPro variant) with mutations (RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, K417N, E484K, N501Y) to maintain an antigenically optimal prefusion conformation, produced in HEK293T cells, purified by ultracentrifugation, expressing EGFP as a reporter. |
| Mutations |
RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, K417N, E484K, N501Y |
| Source |
HEK293T cells |
| Reporter |
EGFP |
| Applications |
- Screening SARS-CoV-2 neutralizing antibodies
- Assessing vaccine efficacy
|
| Titer |
>1 × 107 RFU/mL or >1 × 105 TU/mL |
| Storage |
-80°C |
| Shipping |
Dry ice |
| References |
- Zost, S. J., et al. (2020). Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Scientific Reports, 10, 19076. doi:10.1038/s41598-020-76135-w.
- Starr, T. N., et al. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science, 371(6531), 850–854. doi:10.1126/science.abf9302.
|
|